Fibroblast Growth Factor 2 (FGF2) is Necessary for the Antidepressant Effects of Fluoxetine in Chronically Stressed Mice

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat or click here to download the PDF file.

Click here to download the PDF file.

Creator: 

Shail, Pragya Manjusha

Date: 

2019

Abstract: 

Previous research has shown that fibroblast growth factor 2 protein (FGF2) can act as an anxiolytic and anti-depressive agent in rodents. Hippocampal FGF2 are decreased in post-mortem brains of individuals with mood disorders. No changes in FGF2 noted in the post-mortem brains of individuals with mood disorders that were successfully treated with anti-depressant medication. Mutations in FGF2 gene in humans have predicted non-responsiveness to the therapeutic effects of selective serotonin reuptake inhibitors (SSRIs). These findings suggest FGF2 may be required for the therapeutic effects of antidepressants. To test this, we employed a rodent model of depressive behaviour, chronic variable stress (CVS) with antidepressant treatment (fluoxetine) in wild-type and FGF2 knockout mice and examined depressive and anxiety behaviors. We hypothesized that fluoxetine will reverse the effects of CVS on these behaviours in wild-type mice, but not in FGF2KO, suggesting that FGF2 gene is necessary for the therapeutic effects of fluoxetine.

Subject: 

Mental Health
Neuroscience
Psychology - Behavioral

Language: 

English

Publisher: 

Carleton University

Thesis Degree Name: 

Master of Science: 
M.Sc.

Thesis Degree Level: 

Master's

Thesis Degree Discipline: 

Neuroscience

Parent Collection: 

Theses and Dissertations

Items in CURVE are protected by copyright, with all rights reserved, unless otherwise indicated. They are made available with permission from the author(s).